Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNASDAQ:AVEONASDAQ:ENLVNASDAQ:SAVA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsENLVEnlivex Therapeutics$1.40-5.4%$3.36$1.15▼$4.59$26.00M1.02166,908 shs92,329 shsSAVACassava Sciences$21.19-0.4%$21.83$12.32▼$32.10$916.47M-0.45764,200 shs966,540 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-88.78%AVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ENLVEnlivex Therapeutics+2.07%-62.81%-64.59%-44.57%-48.97%SAVACassava Sciences+1.14%-13.22%-0.05%-17.94%+21.27%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics2.8351 of 5 stars3.55.00.00.01.80.81.3SAVACassava Sciences3.466 of 5 stars3.51.00.04.73.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/AAVEOAVEO PharmaceuticalsN/AN/AN/AN/AENLVEnlivex Therapeutics3.00Buy$7.00400.00% UpsideSAVACassava Sciences3.00Buy$124.00485.18% UpsideCurrent Analyst RatingsLatest SAVA, AVEO, ADMP, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $7.003/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00AVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/AENLVEnlivex Therapeutics-$29.07M-$1.56N/AN/AN/AN/A-71.00%-59.08%6/21/2024 (Estimated)SAVACassava Sciences-$97.22M-$2.32N/A12.69N/AN/A-57.53%-52.58%5/6/2024 (Estimated)Latest SAVA, AVEO, ADMP, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19AVEOAVEO Pharmaceuticals0.942.372.35ENLVEnlivex TherapeuticsN/A5.577.34SAVACassava SciencesN/A9.139.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%AVEOAVEO Pharmaceuticals49.95%ENLVEnlivex Therapeutics1.02%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%AVEOAVEO Pharmaceuticals3.29%ENLVEnlivex Therapeutics12.28%SAVACassava Sciences9.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableENLVEnlivex Therapeutics5018.57 million16.29 millionOptionableSAVACassava Sciences2943.25 million39.35 millionOptionableSAVA, AVEO, ADMP, and ENLV HeadlinesSourceHeadlineRail heralded as future for Thai logisticsbangkokpost.com - April 17 at 1:27 PMCassava Sciences (NASDAQ:SAVA) Trading 6.2% Higher marketbeat.com - April 16 at 3:43 PMCassava Sciences (NASDAQ:SAVA) Sees Large Volume Increasemarketbeat.com - April 15 at 2:49 PMRedemption Date Announced for Warrantsglobenewswire.com - April 15 at 9:20 AMContrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV)americanbankingnews.com - April 15 at 1:44 AMNicklaus: Path to world food security goes through St. Louisstltoday.com - April 14 at 7:17 AMCassava Sciences (NASDAQ:SAVA) Shares Down 9% americanbankingnews.com - April 14 at 4:42 AMCassava Sciences (NASDAQ:SAVA) Trading Down 9%marketbeat.com - April 12 at 2:51 PMVietnam has great potential for biofuel: expertsvietnamnet.vn - April 12 at 2:00 PMCassava Sciences Sees Unusually Large Options Volume (NASDAQ:SAVA)americanbankingnews.com - April 12 at 3:52 AMInvestors Purchase Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA)marketbeat.com - April 11 at 4:50 PMCassava Sciences (NASDAQ:SAVA) Sees Strong Trading Volumemarketbeat.com - April 9 at 3:19 PMFosukrom farmers trained on organic herbicides, pesticidesmodernghana.com - April 8 at 8:15 PMZambians Feel the Personal Consequences of Climate Change—and Dream of a Sustainable Futureinsideclimatenews.org - April 8 at 8:15 PMCassava Sciences (NASDAQ:SAVA) Trading Up 5.7%marketbeat.com - April 8 at 1:46 PMGates Foundation’s agtech arm sets up shop in St. Louis to help smallholders in Africaagfundernews.com - April 5 at 2:17 AM5 Foods You Must Eat For A Longer, Healthier Life - Blue Zones Expert Revealsfood.ndtv.com - April 5 at 1:13 AMAg nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employeesbizjournals.com - April 5 at 1:13 AMStrong quake rocks Taiwan, tsunami warnings issuedmsn.com - April 4 at 4:16 PMCan Africa one day help feed the world’s growing population?ft.com - April 3 at 3:22 AMElevating knowledge about Africa in international business: KNUST’s Prof. Nathaniel Boso’s legacymyjoyonline.com - April 2 at 5:22 PM24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassavastockhouse.com - April 2 at 5:22 PMTracing science’s transformative impact on manifesto implementationmsn.com - April 2 at 10:59 AMFINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firmaccesswire.com - April 1 at 11:00 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.AVEO PharmaceuticalsNASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Enlivex TherapeuticsNASDAQ:ENLVEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.